# Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

> **NCT04362670** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ocular Therapeutix, Inc.** · enrollment: 153 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** OTX-CSI
- **OTHER:** Placebo Vehicle

## Key facts

- **NCT ID:** NCT04362670
- **Lead sponsor:** Ocular Therapeutix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-23
- **Primary completion:** 2021-08-11
- **Final completion:** 2021-08-11
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04362670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04362670, "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04362670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*